Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $6.2 million.

  • GeneDx Holdings' Capital Expenditures rose 65544.68% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 25182.44%. This contributed to the annual value of $5.5 million for FY2024, which is 459.05% up from last year.
  • Per GeneDx Holdings' latest filing, its Capital Expenditures stood at $6.2 million for Q3 2025, which was up 65544.68% from $2.4 million recorded in Q2 2025.
  • GeneDx Holdings' Capital Expenditures' 5-year high stood at $6.2 million during Q3 2025, with a 5-year trough of $112000.0 in Q3 2023.
  • For the 5-year period, GeneDx Holdings' Capital Expenditures averaged around $2.3 million, with its median value being $2.4 million (2025).
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 9449.9% in 2023, then soared by 128352.14% in 2025.
  • GeneDx Holdings' Capital Expenditures (Quarter) stood at $2.6 million in 2021, then plummeted by 74.52% to $672000.0 in 2022, then surged by 253.57% to $2.4 million in 2023, then rose by 21.17% to $2.9 million in 2024, then soared by 114.38% to $6.2 million in 2025.
  • Its Capital Expenditures was $6.2 million in Q3 2025, compared to $2.4 million in Q2 2025 and $6.1 million in Q1 2025.